非拉尼布联合泊马度胺和地塞米松治疗难治性多发性骨髓瘤患者的安全性和有效性及其与α1-酸性糖蛋白(AAG)水平的关联:西班牙骨髓瘤组开展的Ib/II期Pomdefil临床试验
这项Ib/II期试验评估驱动蛋白纺锤体蛋白抑制剂非拉尼布联合泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤(RRMM)患者。47例RRMM患者(中位既往治疗线数3线,94%来那度胺难治)入组,II期31例中18例达到至少轻微缓解(MR),达到预设成功阈值。全组51%达部分缓解(PR)及以上,60%达MR及以上,中位无进展生存期(mPFS)7个月,总生存期(OS)19个月;主要毒性为血液学毒性。基线血清AAG<800 mg/l者疗效更优(总缓解率62% vs 17%,P=0.04),mPFS更长(9 vs 2个月,P=0.014)。
要点
- 非拉尼布联合泊马度胺和地塞米松在RRMM中有效,但伴显著血液学毒性。
- II期31例中18例达至少MR,达到预设成功阈值。
- 基线AAG<800 mg/l者总缓解率62% vs 17%(P=0.04),mPFS 9 vs 2个月(P=0.014)。
核心结论
- 非拉尼布联合泊马度胺和地塞米松在RRMM中有活性,但伴显著血液学毒性。
- 基线AAG高水平可识别不太可能对该策略应答的患者。
研究设计与样本
- Ib/II期临床试验(Pomdefil),由西班牙骨髓瘤组开展,纳入47例RRMM患者,中位既往治疗线数3线(范围2-8),94%来那度胺难治;I期14例,II期33例。
- 推荐剂量为非拉尼布1.25 mg/m2于第1、2、15、16天给药,泊马度胺4 mg第1-21天,地塞米松40 mg每周一次。
主要发现
- II期31例中18例达到至少轻微缓解(MR),达到预设成功阈值。
- 全组51%达部分缓解(PR)及以上,60%达MR及以上,中位无进展生存期(mPFS)7个月,总生存期(OS)19个月。
- 主要毒性为血液学毒性。
- 基线血清AAG<800 mg/l者总缓解率62% vs 17%(P=0.04),mPFS 9 vs 2个月(P=0.014)。
关键数值与推荐
- II期预设成功阈值:31例中18例达至少MR。
- 全组缓解率:≥PR 51%,≥MR 60%;mPFS 7个月,OS 19个月。
- 基线AAG<800 mg/l者总缓解率62% vs 17%(P=0.04),mPFS 9 vs 2个月(P=0.014)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase I/II trial evaluated the combination of the kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) patients. Forty-seven RRMM patients with a median of three prior lines (2-8) and 94% refractory to lenalidomide were included: 14 in phase I and 33 in phase II. The recommended dose was 1·25 mg/m2 of filanesib on days 1, 2, 15, 16, with pomalidomide 4 mg on days 1-21 and dexamethasone 40 mg weekly. The defined threshold for success was achieved, with 18 out of 31 patients obtaining at least minor response (MR) in the phase II. In the global population, 51% of patients achieved at least partial response (PR) and 60% ≥MR, resulting in a median progression-free survival (mPFS) of seven months and overall survival (OS) of 19 months. The main toxicity was haematological. Importantly, patients with low serum levels of alpha 1-acid glycoprotein (AAG) at baseline (<800 mg/l) had a superior response (overall response rate of 62% vs. 17%; P = 0·04), which also translated into a longer mPFS (9 vs. 2 months; P = 0·014). In summary, filanesib with pomalidomide and dexamethasone is active in RRMM although with significant haematological toxicity. Most importantly, high levels of AAG can identify patients unlikely to respond to this strategy. Trial registration: clinicaltrials.gov identifier: NCT02384083.
引用
- Ocio EM, Motlló C, Rodríguez-Otero P, et al. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. Br J Haematol. 2020. PMID: 32501528. doi:10.1111/bjh.16788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。